浙江天册律师事务所 关于 浙江华海药业股份有限公司 2024 年年度股东大会的 法律意见书 浙江省杭州市杭大路 1 号黄龙世纪广场 A 座 11 楼 310007 电话：0571-87901111 传真：0571-87901500 法律意见书 浙江天册律师事务所 关于浙江华海药业股份有限公司 2024 年年度股东大会的 法律意见书 编号：TCYJS2025H0659 号 致：浙江华海药业股份有限公司 浙江天册律师事务所（以下简称"本所"）接受浙江华海药业股份有限公司（以 下简称"华海药业"或"公司"）的委托，指派本所律师参加公司 2024 年年度股 东大会，并根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）和《上市公司股东会规则》（以 下简称"《股东会规则》"）等法律、法规和其他有关规范性文件的要求及《浙江 华海药业股份有限公司章程》（下称"《公司章程》"）《浙江华海药业股份有限公 司股东大会议事规则》（下称"《议事规则》"）的规定出具本法律意见书。 在本法律意见书中，本所律师仅对本次股东大会召集、召开程序、出席人员的 资格、召集人的资格、表决程序及 ...

| 证券简称：华海药业 | 证券代码：600521 | 公告编号：临 2025-064 号 | | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | 浙江华海药业股份有限公司 第九届董事会第一次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下称"公司"）第九届董事会第一次临时会 议于二零二五年五月二十三日在公司四楼会议室以现场方式召开。会议应到会董 事九人，实际到会董事九名，符合召开董事会会议的法定人数。会议由公司董事 李宏先生主持，公司高级管理人员列席了会议。会议程序符合《中华人民共和国 公司法》（以下简称"公司法"）及《浙江华海药业股份有限公司公司章程》（以 下简称"公司章程"）的规定，会议合法有效。会议审议并通过了如下决议： 一、审议通过了《关于选举公司董事长的议案》； 表决情况：同意：9 票；反对：0 票；弃权：0 票。 会议决议：选举李宏先生为公司董事长，任期至第九届董事会届满。 二、审议通过了《关于聘任公司总裁的议案 ...

市场继续缩量，全天走出小幅冲高回落的普跌行情。 1、行情 题材方面，医药板块继续大涨，永安药业3连板，海森药业、海翔药业2连板，众生药业、多瑞医药（20CM）、海辰药业（20CM）、新天地 （20CM）先后涨停，科源制药、华海药业、常山药业等大涨，三生国健早盘一度跌超10%，午后迎来反弹最终跌幅收窄至3.56%； 2、核电 今日开盘，核电、核聚变板块集体反弹。 尚纬股份一字（2板），融发核电、哈焊华通（20CM）、雪人股份开盘快速涨停； 核聚变开盘走强，王子新材6天5板，尚纬股份2板，融发核电、哈焊华通（20CM）、雪人股份、中洲特材（20CM）纷纷涨停，常辅股份、国光 电气、合锻智能、中核科技、兰石重装等盘中均有大涨表现； 量子科技盘中局部发力，格尔软件涨停，禾信仪器、科大国创、国盾量子、神州信息、吉大正元、复旦复华等或大幅高开或盘中大涨，但整体呈 现冲高回落走势； 无人驾驶整体也冲高回落，德迈仕20CM涨停（T字），动力新科（炸）、万安科技（炸）涨停，东土科技、天迈科技、合众思壮、美湖股份、 天准科技、经纬恒润、浙江世宝等早盘均集体大涨； 汽车整车、零部件板块局部发力，赛力斯、汉马科技（炸）涨停，隆盛科技 ...

Group 1 - China Communication Technology Co., Ltd. won a total of 11 important rail transit projects with a total bid amount of approximately 3.789 billion yuan, accounting for 11.67% of the company's audited revenue for 2024 [1] - New Chai Co., Ltd. plans to use no more than 500 million yuan of idle funds to purchase low-risk financial products to improve fund efficiency [2] - Qingshan Paper Industry's controlling shareholder intends to restructure and inject assets into Fujian Provincial Industrial Holding Group [3] Group 2 - BWS hired Liu Xiaodan as Senior Vice President, effective immediately [4] - Huakang Clean won a bid for a purification project at the Tengzhou Medical and Health Center, with a bid price of 60.2394 million yuan [6] - Silver Dragon Co., Ltd. announced that several executives plan to reduce their holdings by a total of no more than 550,000 shares due to personal financial needs [8] Group 3 - Intercontinental Oil & Gas plans to invest 848 million USD in the South Basra Integrated Project in Iraq, holding a 67% stake [13] - Huatai Dain's subsidiary received a drug registration certificate for sodium valproate oral solution, used for treating epilepsy [14] - Hainan Mining's 20,000-ton battery-grade lithium hydroxide project has achieved full-process connectivity and produced qualified products [29] Group 4 - Roman Co., Ltd.'s subsidiary won a significant overseas project in Saudi Arabia with a bid amount of approximately 200 million yuan [30] - Measurement Co., Ltd. completed a capital reduction for its subsidiary, optimizing resource allocation [31] - Guodian Nanzi plans to increase capital by 45 million yuan for its wholly-owned subsidiary to meet market expansion needs [32] Group 5 - Eighty Billion Space plans to repurchase shares with a total amount not less than 50 million yuan and not exceeding 100 million yuan [33] - Tianyin Electromechanical's director plans to reduce holdings of no more than 0.25% of the company's shares [34] - Hailier's subsidiary passed environmental protection acceptance for its agricultural chemical preparation project [35] Group 6 - Kelong Pharmaceutical's subsidiary will present innovative drug research results at the ASCO annual meeting [36] - Zhonghong Medical's subsidiary received medical device registration certificates for enteral nutrition pumps and injection pumps [37] - Luyou Pharmaceutical received a drug registration certificate for amlodipine besylate tablets, used for hypertension [39]

| 300705 | 九典制 | 0.44 | 3.37 | 660.10 | 3.35 | | --- | --- | --- | --- | --- | --- | | | 药 | | | | | | 600572 | 康恩贝 | 0.68 | 1.45 | 627.79 | 3.76 | | 002349 | 精华制 | 0.81 | 2.27 | 571.95 | 4.13 | | | 药 | | | | | | 002004 | 华邦健 | 0.25 | 0.80 | 571.40 | 9.29 | | | 康 | | | | | | 688553 | 汇宇制 | 1.93 | 1.88 | 555.55 | 5.80 | | | 药 | | | | | | 300086 | 康芝药 | -0.39 | 3.88 | 517.25 | 5.87 | | | 业 | | | | | | 002907 | 华森制 | 3.77 | 5.14 | 493.67 | 2.10 | | | 药 | | | | | | 000908 | *ST景峰 | 1.19 | 2.66 | 475.12 | 3.98 | ...

Group 1 - The cell immunotherapy concept index rose by 1.35%, ranking third among concept sectors, with 35 stocks increasing in value, including Seer Medical which hit the daily limit, and Sunshine Nuohuo, Shutai Shen, and Betta Pharmaceuticals showing significant gains of 12.55%, 11.77%, and 8.35% respectively [1] - The concept sector saw a net inflow of 246 million yuan, with 29 stocks receiving net inflows, and 5 stocks attracting over 50 million yuan in net inflows, led by Huahai Pharmaceutical with a net inflow of 143 million yuan [1] - The top stocks by net inflow included Seer Medical, Huadong Medicine, and Saifutian, with net inflows of 126 million yuan, 106 million yuan, and 74 million yuan respectively [1] Group 2 - The leading stocks by net inflow ratio were Saifutian, Seer Medical, and Hai Xin Co., with net inflow ratios of 20.66%, 18.75%, and 15.23% respectively [2] - Huahai Pharmaceutical had a daily increase of 7.45% with a turnover rate of 7.28%, while Seer Medical increased by 10.04% with a turnover rate of 30.03% [2] - Other notable stocks included Betta Pharmaceuticals with an 8.35% increase and a turnover rate of 5.70%, and Rongchang Bio with a 2.08% increase and a turnover rate of 4.97% [2] Group 3 - Stocks with significant declines included Yaoji Technology, Hainan Hai Pharmaceutical, and Nearshore Protein, which fell by 4.24%, 3.62%, and 3.19% respectively [1] - The overall performance of the cell immunotherapy sector reflects a positive trend, with a majority of stocks experiencing gains, indicating investor confidence in this area [1][2] - The data suggests a strong interest from institutional investors in the cell immunotherapy sector, as evidenced by the substantial net inflows into key stocks [1][2]

Group 1 - The innovative drug concept index rose by 0.97%, ranking 7th among concept sectors, with 116 stocks increasing in value [1] - Notable gainers included Hai Chen Pharmaceutical, which hit the daily limit with a 20% increase, and other companies like Xian Da Co., Zhong Sheng Pharmaceutical, and Hai Xiang Pharmaceutical also reached their daily limits [1] - The top gainers in the sector were Yang Guang Nuo He, Shu Tai Shen, and Bei Da Pharmaceutical, with increases of 12.55%, 11.77%, and 8.35% respectively [1] Group 2 - The innovative drug sector saw a net inflow of 438 million yuan, with 81 stocks receiving net inflows, and 5 stocks exceeding 100 million yuan in net inflows [2] - Hai Chen Pharmaceutical led the net inflow with 179 million yuan, followed by Zhong Sheng Pharmaceutical, Hua Hai Pharmaceutical, and Xian Da Co. with net inflows of 177 million yuan, 143 million yuan, and 110 million yuan respectively [2][3] - The net inflow ratios for Zhong Sheng Pharmaceutical, Xian Da Co., and Hai Chen Pharmaceutical were 42.93%, 17.67%, and 15.92% respectively [3] Group 3 - The innovative drug sector's performance was highlighted by the significant trading volume and turnover rates, with Hai Chen Pharmaceutical showing a turnover rate of 39.86% [3] - Other companies with notable turnover rates included Zhong Sheng Pharmaceutical at 3.92% and Hua Hai Pharmaceutical at 7.28% [3] - The overall market sentiment in the innovative drug sector appears positive, with several stocks experiencing substantial gains and strong capital inflows [2][3]

Group 1 - The A-share market has returned to levels seen before April 2, indicating an upward adjustment in economic expectations for the second quarter, which may enhance risk appetite [1] - The market is expected to focus on structural trends, with a potential rotation between dividend and technology sectors contributing to excess returns [1] - The A500 index, designed with an "industry balance" approach, provides a natural barbell structure by evenly distributing investments between dividend and technology sectors [1] Group 2 - The A500 ETF (159339) has shown a high market activity with an average daily trading volume of 261 million yuan over the past 20 trading days [1] - In the A500 index, stocks such as Betta Pharmaceuticals and Sihuan Pharmaceutical have risen over 9%, while Huahai Pharmaceutical and Tigermed have increased over 7% [1] - The A50 ETF (159592) tracks the A50 index, which focuses on large-cap leading stocks across various industries, benefiting from increased market concentration due to supply-side reforms [2] Group 3 - Recent trade negotiations have led to a temporary recovery in market sentiment, but subsequent pullbacks indicate a return to rationality among investors, focusing more on fundamental support [2] - The previous rise in A-shares was primarily driven by event-based sentiment rather than substantial improvements in corporate earnings or macroeconomic conditions [2] - As short-term sentiment factors fade, capital pricing is expected to align more closely with actual business performance and industry development trends [2]

Group 1 - The core viewpoint highlights the active trading and positive performance of the China A500 ETF Morgan and A500 Enhanced ETF Morgan, with the CSI A500 Index showing a slight increase of 0.14% as of 13:36 on May 23, 2025 [1] - Notable stocks within the CSI A500 Index include Siasun (601127) reaching a daily limit increase, Betta Pharmaceuticals (300558) rising by 12.02%, Huahai Pharmaceutical (600521) increasing by 8.47%, Tigermed (300347) up by 7.92%, and Xinlitai (002294) gaining 5.65% [1] Group 2 - Institutions emphasize the increasing asset allocation value in China, with "Opportunities in China amid Global Changes" becoming a significant topic in mid-term strategy outlooks [3] - The Chinese economy is showing steady improvement, supported by a combination of market stabilization policies that inject more certainty into the capital market, enhancing the attractiveness of Chinese assets [3] - Brokerages generally view Chinese assets as having both risk-hedging properties and long-term allocation value, positioning them as a "safe haven" for global funds [3] - Morgan Asset Management is focused on identifying relatively "certain" quality asset investment opportunities, launching the international "Dividend Toolbox" series of preferred funds to provide diversified dividend investment solutions for Chinese investors covering A-shares, Hong Kong stocks, and Asian markets [3]

Core Viewpoint - The innovative pharmaceutical concept stocks are experiencing significant growth, with notable companies reaching historical highs [1] Group 1: Stock Performance - Xinlitai and Kelun Pharmaceutical both achieved historical highs in stock prices [1] - Yangguang Nuohe is approaching a 20% daily limit increase [1] - Zhongsheng Pharmaceutical previously hit a daily limit increase [1] - Haichen Pharmaceutical, Beida Pharmaceutical, and Hongbo Pharmaceutical saw stock prices rise over 10% [1] - Shutaishen, Haixiang Pharmaceutical, Tigermed, and Huahai Pharmaceutical experienced stock price increases of over 5% [1]